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Abstract
Background: Linear endoscopic ultrasonography (EUS) allows the visualization, identification, and characterization
of the extent of lesions of the gastrointestinal (GI) tract and adjacent structures. EUS-guided fine-needle aspiration
(EUS-FNA) facilitates a more accurate diagnosis of mediastinal, intra-abdominal, and pancreatic lesions through the
collection of the cytological material under direct visualization. Recent reports suggest that histological samples can
be obtained by EUS-FNA with a reverse, bevel-tipped needle (the ProCore needle) to collect the core samples (fine
needle biopsy, FNB), thereby adding a new dimension to the diagnostic usefulness of this technique. Certain
neoplasms, such as lymphoma and stromal tumors, can be assessed by EUS-FNB to confirm the diagnosis.
Here, we aimed to carry out a prospective, multicenter, single-blind, randomized, controlled trial to compare
EUS-FNB and EUS-FNA.
Methods/design: A total of 408 patients will be enrolled from five endoscopic centers. Patients will be divided into
two groups: (1) group A, which is the EUS regular needle group (EUS-FNA) and (2) group B, which is the EUS ProCore
needle group (EUS-FNB). Patients in group A will be examined with a 22G EchoTip Ultra needle, and patients in group
B, with a 22G EchoTip ProCore needle. For all included patients, four EUS-guided passes will be made in each lesion. In
the first and second pass, a slow-pull suction method of the stylet will be done. The third and fourth pass will use
manual suction of 5 cc. The primary objective is to compare the diagnostic yield of malignancy by EUS-FNA versus
EUS-FNB.
Discussion: The trial will compare samples obtained by EUS-FNA versus EUS-FNB for the diagnostic yield of solid
lesions. The efficacy of these two sampling methods will be assessed on various lesions, which may provide insights
into developing practice guidelines for their future indications.
Trial registration: Clinical Trials.gov, NCT02327065.
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Background
Linear endoscopic ultrasonography (EUS) allows the
identification of suspected malignancies by creating
real-time images of the digestive tract and adjacent
lesions [1]. EUS-guided fine needle aspiration (FNA)
offers an opportunity for sampling mediastinal, intra-
abdominal, and pancreatic lesions under direct
visualization [2]. Since its original description in the
early 1990s, EUS-FNA has been used to obtain cyto-
logical material, thereby contributing to the prompt
and accurate diagnosis of clinically suspected lesions
[3–6]. The diagnostic accuracy of EUS-FNA is gener-
ally high, from 52 % to 94 % [7–10]. Cytopathology
plays an important role in improving the diagnostic
yield. Notably, distinguishing the inflammatory lesion
caused by a reaction and regeneration from well-
differentiated neoplasia solely based on cytological
evaluation can be difficult. Moreover, certain neoplasms,
such as lymphoma and stromal tumors, require histo-
logical exams to assess the tissue architecture and cell
morphology changes in order to confirm the diagnosis
[11]. To overcome this limitation, a new fine needle biopsy
(FNB) device has been designed (Cook Endoscopy, Limer-
ick, Ireland). The new ProCore needle was designed with
a reverse bevel at the tip to collect a core sample. A multi-
center study on 114 patients showed that the application
of the ProCore needle (EUS-FNB) led to 85.96 % diagnos-
tic accuracy; 90.2 % sensitivity to malignancy, 99 % specifi-
city, 100 % positive predictive value (PPV), 78.9 %
negative predictive value (NPV), and 92.9 % accuracy [11].
Overall, most studies favored EUS-FNB for achieving an
adequate histological specimen and high diagnostic yield
compared to EUS-FNA [11–16]. However, several studies
have suggested that the diagnostic yields of EUS-FNB and
EUS-FNA were similar [17–19]. Therefore, the impact of
the needle type (ProCore or regular) on the diagnostic
yield needs to be further studied. We plan to carry out a
randomized controlled trial to compare the diagnostic
yield of EUS-FNA versus EUS-FNB and to assess the sam-
ple quality obtained by both the slow-pull and the suction
approaches.
Methods/design
The study was approved by The Ethics Committee of
Tongji Medical College, Huazhong University of Science
and Technology (HUST) (IORG No: IORG0003571). In-
formed consent will be obtained from the patients or
from their closest relatives with authorization.
Study design
A total of 408 patients from five endoscopic centers in
China will be enrolled in this prospective, multicenter,
randomized, controlled trial. They will be randomly di-
vided into two groups: (1) group A, which will receive
the EUS procedure using the regular needle (EUS-FNA,
22G EchoTip Ultra needle, Cook Endoscopy, Limerick,
Ireland) and (2) group B, which will receive the EUS
procedure using the ProCore needle (EUS-FNB, 22G
EchoTip ProCore needle, Cook Endoscopy, Limerick,
Ireland). The recruitment process flowchart is shown
in Fig. 1.
Objectives
The primary objective of this study is to compare
EUS-FNA versus EUS-FNB for the diagnostic yield
(%) of malignancy [13]. The secondary objectives are
to compare EUS-FNA versus EUS-FNB for 1) the
overall diagnostic yield (%) from solid lesions; 2) the
diagnostic yield (%) from pancreatic and nonpancrea-
tic solid lesions, 3) the crossover diagnostic yield (%),
and 4) the sample quality obtained by either the
slow-pull or suction approaches, respectively.
Setting
A total of 408 patients will be recruited from five
endoscopic centers, including Tongji Hospital, Tongji
Medical College, HUST, Wuhan; Cancer Institute &
Hospital, Chinese Academy of Medical Sciences, Peking
Union Medical College, Beijing; Fudan University
Shanghai Cancer Center, Shanghai Medical College,
Fudan University, Shanghai; Sun Yat-sen University
Cancer Center, Guangzhou; and the First Affiliated
Hospital, College of Medicine, Zhejiang University,
Hangzhou. All clinic sites meet the following criteria:
(1) at least 48 patients can be recruited per site; (2)
at least 2 to 4 trained physician(s) and nurse practi-
tioner(s) per center can participate in the trial; and 3)
the site agrees to strictly abide by the study protocol.
Eligibility
Inclusion criteria
Patients who meet the following inclusion criteria will
be recruited to the trial:
1) Age > 18 years old
2) Sex: male or female
3) Patients who require endoscopic ultrasound and
tissue sampling after imaging examination (MRI, CT,
and ultrasonography) that shows either pancreatic,
intra-abdominal, mediastinal, or pelvic cavity solid
lesions (size > 1 cm)
4) Patients who are willing to be examined in the trial
centers
5) Patients who are able to give consent
Exclusion criteria
Patients will be excluded from the trial for any of the
following reasons:
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1) Hemoglobin ≤ 8.0 g/dL
2) Pregnant female
3) Patient has any coagulation disorder (PLT < 50,000/
mm3, INR > 1.5)
4) History of taking oral anticoagulation agents such as
aspirin, warfarin, etc. in past week
5) Experienced acute pancreatitis in past 2 weeks
6) Has cardiorespiratory dysfunction that cannot
tolerate the operation
7) Has mental diseases or drug addiction
8) Unable to provide informed consent
Randomization and blinding
The randomization will be conducted at the study office
at the School of Public Health, Tongji Medical College,
HUST. A stratified block randomization will be used,
and the block size is 8. The patients will be allocated
randomly to either group A (EUS-FNA) or group B
(EUS-FNB) (1:1).
A data manager, who will not be involved in the
data analysis or patient enrollment, will generate the
randomization schedule. To ensure allocation conceal-
ment, the randomization schedule will be sealed
under scratch cards (001–408). The scratch cards will
not be opened until the baseline assessment is
completed and the patient has consented to partici-
pate in the study.
The randomization schedule will not be available to
the study recruiters or echoendoscopists until the base-
line assessment is completed. Only the study coordina-
tors have access to the randomization schedule. The
cytologists and pathologists will be blinded during the
entire study.
Interventions
Patients will be allocated randomly into group A
(EUS-FNA, n = 204) or group B (EUS-FNB, n = 204).
Group A patients will be examined with the 22G
EchoTip Ultra needle, and group B will be examined
with the 22G EchoTip ProCore needle.
The procedure will be performed under deep sedation
according to the principles of “monitored anesthesia
care.” The patients will be anesthetized with intravenous
administration of propofol by trained anesthetists. All
patients will receive oxygen during the procedures;
blood pressure and heart rate will be monitored. Once
the lesion is evaluated by EUS, the echoendoscopist will
select the shortest pathway, while avoiding blood vessels,
to reach the lesion. Under real-time visualization, each




Allocated to EUS-FNA group 
Received 22G EchoTip Ultra needle
(1-2 passes slow pull; 3-4 passes 5-ml suction)
Allocated to EUS-FNB group  
Received 22G EchoTip ProCore needle           
(1-2 passes slow pull; 3-4 passes 5-ml suction)
Pathology assessment and cytology assessment1
Crossover to the alternative needle2
Follow-up3
Analysis
Fig. 1 CONSORT flowchart illustrating the randomization and recruitment process in the study. 1 Each slide will be assessed by two independent
experts. The cytologists and pathologists will follow the protocol to assess the samples and will be blinded as to which technique is
used for which specimen. 2 If diagnostic failure occurs, the patient will be allowed to crossover to the other group after agreeing to
accept a needle biopsy again on the same lesion 1 week later. 3 Three follow-up points are scheduled after the biopsy (1-week postoperational
follow-up, 12-week follow-up, and 48-week follow-up); thereafter, the follow-ups will be conducted via telephone interviews or outpatient interviews.
Once the surgical pathologic results are obtained, we will stop the follow-up
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eliminate technical biases, the same procedure for
obtaining samples will be applied to each patient under-
going EUS-FNA or EUS-FNB.
Technique for EUS-FNA and EUS-FNB
1) The first and second needle passes (slow pull) [20]:
The needle will be advanced into the lesion under real-
time EUS visualization. Back and forth movements will
be made 20 times within the lesion and will be per-
formed using simultaneous minimal negative pressure
by pulling the needle stylet slowly and continuously.
2) The third and fourth needle passes (5-ml suc-
tion) [18]: After the needle has been advanced into the
lesion under real-time EUS visualization, the stylet will
be removed. Continuous suction will be applied with a
5-ml syringe, and the needle will be moved back and
forth 20 times within the lesion. Suction will be released,
and then, the needle will be withdrawn from the lesion.
After biopsy, the samples will be labeled immediately
with numbers in the order of the needle pass. Samples
will be prepared for histological and cytological exami-
nations. The cytologists and pathologists will always be
blinded regarding which technique was used for which
specimen.
After the selected lesion has been punctured during
the four needle passes, if no core tissue is obtained or if
the operators determine the specimens are insufficient
according to the results of the macroscopic onsite evalu-
ation (MOSE) [21], the operators will use a proper punc-
ture method to obtain samples as the backup procedure.
If diagnostic failure occurs, the patient will crossover
to the other arm after agreeing to accept a needle biopsy
again on the same lesion 1 week later with the same
method mentioned above.
Assessment standards
After patient recruitment is completed, all samples will
be reassessed by selected cytologists and pathologists
from Tongji Hospital, Tongji Medical College, HUST,
and from the Cancer Institute & Hospital, Chinese
Academy of Medical Sciences, Peking Union Medical
College. They will assess the samples following the
protocol and remain blinded regarding which technique
was used for which specimen. Each sample will be
assessed by two independent experts. If the two experts
have different judgments, they should discuss it together
and make a final decision [7].
Histology assessment criteria
The histological assessment will involve the following:
1) Tissue integrity assessment [20, 22]
Grade A: core tissue (an architecturally intact
piece of tissue measuring at least 550 micron in
greatest axis, as the diameter of a high-power
microscopic field), clearly characterizes the lesion
sufficient for diagnosis
Grade B: core fragments present, tissue does not
meet the criteria for architecturally intact
histology but can still yield a diagnosis based on
cell morphology
Grade C: no lesion tissue found and cannot yield a
diagnosis
2) Blood cell contamination assessment [18]
Grade A: little blood contamination, minimal
surface area (SA) < 25 % of slide
Grade B: medium blood contamination, 25–50 %
of the slide
Grade C: much blood contamination, SA > 50 % of
the slide
Cytology assessment criteria
The cytological assessment involves the following:
1) Cellularity assessment [9]
Grade A: satisfactory, more than four clusters,
with a minimum of ten cells in each cluster
Grade B: adequate, approximately two to four
clusters, with a minimum of ten cells in each
cluster
Grade C: unsatisfactory, fewer than two clusters,
or no cellular smear
2) Blood cell contamination assessment [18]
Grade A: little blood contamination, SA < 25 %
of slide
Grade B: medium blood contamination, 25–50 %
of slide
Grade C: much blood contamination, SA > 50 %
of the slide
Collecting data
Table 1 shows the types of data collected and when the
data should be collected.
Final diagnosis
The reports will be stratified into four diagnostic
categories for the histological and cytological evaluation,
including “positive for malignancy,” “suspicious for ma-
lignancy,” “atypia,” and “negative for malignancy.” The
“positive for malignancy” will be considered if the re-
ports contain words such as “diagnostic for malignancy,”
“compatible with carcinoma,” “consistent with adenocar-
cinoma,” “positive for malignant cells,” “malignant cells
present,” or when specified by the exact tumor type [23].
The “positive for malignancy” will not be considered if
the reports contain words such as “suspicious for malig-
nancy,” “atypia,” or “negative for malignancy.”
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Final diagnostic criteria
The final diagnostic criteria [20] include the following:
1) For patients who undergo surgery, the final
diagnoses will be based on the definite histological
diagnoses from surgical resection specimens.
2) In the absence of surgical pathology, a minimum
48 weeks of clinical follow-up time will be conducted.
If the lesion spontaneously resolves or has no sign of
deterioration in follow-up imaging studies, the lesion
will be considered a benign disease. If the lesion shows
enlargement or metastasis, and the patient presents
malignant symptoms such as weight loss, anemia, or
dies of tumor complications during the follow-up, the
lesion will be considered a malignant disease.
Statistical analysis
Sample size
We assumed that the diagnostic yield of malignancy
for EUS-FNA was 80 % [23] versus 93 % for EUS-
FNB [11, 13]. Because approximately 70 % of patients
are expected to be diagnosed with malignancy [9], the
sample size should be 342, with a power of 85 % and
a two-sided significance level of 5 %. Considering
20 % of patients will be lost to follow-up, the esti-
mated patient number in this trial should be 408.
Data analysis
A two-tailed distribution will be used and a P-value < 0.05
is considered statistically significant. Continuous variables
will be measured as mean (range) and standard deviation
using t tests or Wilcoxon rank-sum tests. Categorical vari-
ables will be measured as the count and percentage using
the χ2 test. The diagnostic yield will be described as a pro-
portion using the χ2 test; the blood contamination and
cellularity in specimens with slow-pull and suction will be
divided into three levels (Grade A, Grade B, and Grade
C), and McNemar’s test for correlated proportions will be
used. All analyses will be performed with SAS version 9.2.
Discussion
The role of EUS-FNA in obtaining cytological materials
is well-established [24]. However, a recent study suggests
the false positive rate of FNA cytology is 5 % to 7 %,
which is higher than the originally reported rates of 0 %
to 1 % [25, 26]. Moreover, an increased interest in histo-
logical tissue sampling under real-time EUS imaging ex-
ists because of the advantage in diagnosing certain
suspected tumor types, such as neuroendocrine tumor
and lymphomas [27]. A standard 19G FNA needle has
been used to obtain histological materials and achieved a
diagnostic accuracy of 94.5 % [28], although the device is
highly associated with technical failures. A Quick-Core
needle was used with an overall diagnostic accuracy of
75 % to 84 % [29, 30]. One drawback of the Quick-Core
needle is that it is difficult to maneuver, especially for
transduodenal biopsy. Recently, a new 22G needle with a
reverse bevel at the tip (EUS-FNB) has become available.
The ProCore needle design combines the features of an
FNA needle with a core biopsy needle [20], which has
Table 1 Study schedule for data collection
Item Interview 1 Interview 2 Interview 3 Interview 4




Blood routine tests X X
Coagulation routine tests1 X
Blood biochemistry tests2 X X
Blood tumor markers tests3 X X X
Complications X X X
Clinical signs4 X X X X
Imaging examination X X X X
Cytology examination X X
Pathology examination X X
Surgical-pathological examination X X X
Therapies X X X
1Coagulation routine tests: prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen, INR
2Blood biochemistry tests: AST, ALT, BUN, Cr, ALP, lipase, amylase
3Blood tumor marker tests: CEA, CA19-9, CA72-4, AFP, SSC, NSE
4 Clinical signs include pain, weight loss, cachexia, etc.
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enhanced flexibility, especially for core tissue collection.
Results from a multicenter study on EUS-FNB showed
that, overall, the operations were completed in 98.24 %
patients, the histological specimens were adequate in
89.47 % patients, and the diagnoses were accurate in
92.9 % patients [11]. EUS-guided tissue acquisition now
seems to be more suitable for histological evaluation
[13, 20]. Here, we carry out a randomized controlled
trial to compare the diagnostic efficiency of EUS-FNB
versus EUS-FNA and to assess the sample quality
obtained by different types of needles with different
methods. To our knowledge, this is the largest cohort
study on EUS-FNB so far. The outcome measurements
will help us to understand the special indications for each
technique and their diagnostic accuracy. In addition,
Aadam et al. reported a significant rescue effect of FNA
crossover to FNB [13]. We specifically designed our trial
to allow the patient to crossover to the other arm if
diagnosis is not achieved after the first round of needle
biopsy, which will help us draw our conclusions.
The success of EUS-FNA is associated with several
factors, including appropriate methods of biopsy, sample
preparation, and onsite cytopathological interpretation
[31]. The onsite cytopathological interpretation may not
always be available during EUS-FNA procedures; there-
fore, appropriate methods of biopsy and sample prepar-
ation are very important. Some echoendoscopists use
slow-pull, and others use constant suction. Suction with
a self-retracting syringe will likely bring more cellularity
but also more blood. In this trial, the echoendoscopist
will use both methods (slow-pull and constant suction)
on each lesion and, hopefully, will be able to draw a
clear conclusion on selecting which biopsy method
should be used for which procedure. Furthermore,
standard procedures and sample preparation methods
will be used to process all types of biopsy samples. For
example, after the needle has been inserted into the
mass, for both FNA and FNB, the needle will be moved
back and forth 20 times within the lesion to collect spec-
imens. The specimens will be expelled from a needle in
three steps: step 1, which involves pushing the stylet into
the needle; step 2, which involves flushing the needle
with 0.1 ml saline; and step 3, which involves filling the
needle with 2 ml of air.
Some limitations exist in the present study design. For
instance, we will not be performing the rapid onsite
evaluation (ROSE) in the current trial. ROSE is most fre-
quently used in the United States, and the absence of an
onsite cytopathologist has been shown to affect the diag-
nostic yield by increasing the number of inadequate
samples. Although its popularity is growing here in
China as well, several alternative strategies, including the
macroscopic onsite evaluation (MOSE), have been re-
ported to improve the diagnostic yield [21]. The well-
trained endoscopists in our centers will apply MOSE
and gross inspection to evaluate the quality of the speci-
mens. Second, although the crossover design is critical,
obtaining agreement from the patients for the second bi-
opsy may be difficult because it may increase the risk of
complications. Consequently, the number of patients re-
cruited may be reduced, thereby leading to suboptimal
conclusions. Third, some patients may not undergo sur-
gery and, hence, will not have any final pathology report.
In addition, the possibility exists that contact with the
patient will be lost during the 48 weeks of follow-up. To
prevent dropout, local research assistants will be re-
cruited to help complete the patient registration in-
formation (record at least two phone numbers) and
ensure that appointments are being made for follow-
up assessments.
Trial status
Patient enrollment began on December 20, 2014 and
completion is expected by December 31, 2015. At
present (December 5, 2015), 372 patients have been en-
rolled in the study.
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